Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Recursion Pharmaceuticals Inc (RXRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Recursion Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.84 -0.10    -1.26%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
7.87
+0.03
+0.38%
19:56:50 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 4,314,464
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 7.48 - 7.88
Recursion Pharmaceuticals 7.84 -0.10 -1.26%

Recursion Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Recursion Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

500

Equity Type

ORD

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Contact Information

Address 41 South Rio Grande Street
Salt Lake City, 84101
United States
Phone 385 269 0203
Fax 801 821 2872

Top Executives

Name Age Since Title
Ramon Martin Chavez Marquez 57 2020 Independent Chair of the Board
Robert J. Lollini 70 2014 Member of Business Advisory Panel
Terry-Ann Burrell 47 2020 Independent Director
Joseph P. Miletich 72 2021 Chairman of Therapeutics Advisory Board
Anne Carpenter - 2014 Member of Scientific and Technical Advisory Board
Najat Khan - 2024 Chief R&D Officer, Chief Commercial Officer & Director
Kirk R. Thomas - 2014 Member of Scientific & Technical Advisory Board
H. Perry Fell 67 2014 Member of Business Advisory Panel
Zavain Dar 35 2016 Independent Director
Dean Y. Li 61 2013 Co-Founder & Independent Director
Zachary S. Bogue 49 2018 Independent Director
Robert M. Hershberg 62 2020 Independent Director
Christopher C. Gibson 41 2013 Co-Founder, CEO & Director
Blake C. Borgeson 42 2013 Co-Founder & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RXRX Comments

Write your thoughts about Recursion Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Charlie Charlie Charlie
Charlie Charlie Charlie Apr 16, 2024 5:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
at the edge of rising or descending.
Neil Young
Neil Young Feb 26, 2024 5:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Buy
upticks boombust
upticks boombust Feb 15, 2024 1:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going bankrupt
shawn mimnaugh
shawn mimnaugh Dec 14, 2023 1:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone have any news to support this uptick in price, volume?
Mary Hill
Mary Hill Aug 09, 2023 9:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Watch it climb up 🚀
Mary Hill
Mary Hill Aug 07, 2023 11:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Don't underestimate nvidia partnership! $100 soon
Mary Hill
Mary Hill Aug 07, 2023 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nvidia partnership 👏
Jul 12, 2023 6:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Rubish
ONUR YILDIRIM
ONUR YILDIRIM Jul 12, 2023 9:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What da hell happened this?
SEOK D
SEOK D May 23, 2022 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
SCAM
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email